282 related articles for article (PubMed ID: 23695381)
1. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities.
Lin CH; Chang TC; Das A; Fang MY; Hung HC; Hsu KC; Yang JM; von Itzstein M; Mong KK; Hsu TA; Lin CC
Org Biomol Chem; 2013 Jun; 11(24):3943-8. PubMed ID: 23695381
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors.
Das A; Adak AK; Ponnapalli K; Lin CH; Hsu KC; Yang JM; Hsu TA; Lin CC
Eur J Med Chem; 2016 Nov; 123():397-406. PubMed ID: 27487569
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
Ye D; Shin WJ; Li N; Tang W; Feng E; Li J; He PL; Zuo JP; Kim H; Nam KY; Zhu W; Seong BL; No KT; Jiang H; Liu H
Eur J Med Chem; 2012 Aug; 54():764-70. PubMed ID: 22795831
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
Feng E; Shin WJ; Zhu X; Li J; Ye D; Wang J; Zheng M; Zuo JP; No KT; Liu X; Zhu W; Tang W; Seong BL; Jiang H; Liu H
J Med Chem; 2013 Feb; 56(3):671-84. PubMed ID: 23330908
[TBL] [Abstract][Full Text] [Related]
5. Molecular modeling and lead design of substituted zanamivir derivatives as potent anti-influenza drugs.
Dholakia D; Goyal S; Jamal S; Singh A; Das A; Grover A
BMC Bioinformatics; 2016 Dec; 17(Suppl 19):512. PubMed ID: 28155702
[TBL] [Abstract][Full Text] [Related]
6. Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses.
Wen WH; Wang SY; Tsai KC; Cheng YS; Yang AS; Fang JM; Wong CH
Bioorg Med Chem; 2010 Jun; 18(11):4074-84. PubMed ID: 20452227
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of novel zanamivir derivatives as potent neuraminidase inhibitors.
Cheng LP; Wang TC; Yu R; Li M; Huang JW
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3622-3629. PubMed ID: 30389293
[TBL] [Abstract][Full Text] [Related]
8. Discovery of acylguanidine oseltamivir carboxylate derivatives as potent neuraminidase inhibitors.
Li Z; Meng Y; Xu S; Shen W; Meng Z; Wang Z; Ding G; Huang W; Xiao W; Xu J
Bioorg Med Chem; 2017 May; 25(10):2772-2781. PubMed ID: 28385598
[TBL] [Abstract][Full Text] [Related]
9. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.
Ikematsu H; Kawai N; Kashiwagi S
J Infect Chemother; 2012 Aug; 18(4):529-33. PubMed ID: 22370919
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of 4-alkyl-2-amino(acetamino)-6-aryl-1,3-thiazine derivatives as influenza neuraminidase inhibitors.
Li W; Xia L; Hu A; Liu A; Peng J; Tan W
Arch Pharm (Weinheim); 2013 Sep; 346(9):635-44. PubMed ID: 23926081
[TBL] [Abstract][Full Text] [Related]
11. Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir.
Liu KC; Lee PS; Wang SY; Cheng YS; Fang JM; Wong CH
Bioorg Med Chem; 2011 Aug; 19(16):4796-802. PubMed ID: 21778065
[TBL] [Abstract][Full Text] [Related]
12. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
Bauer K; Richter M; Wutzler P; Schmidtke M
Antiviral Res; 2009 Apr; 82(1):34-41. PubMed ID: 19428593
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
Xiao M; Xu L; Lin D; Lian W; Cui M; Zhang M; Yan X; Li S; Zhao J; Ye J; Liu A; Hu A
Eur J Med Chem; 2021 Mar; 213():113161. PubMed ID: 33540229
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological activity of thiazole derivatives as novel influenza neuraminidase inhibitors.
Liu Y; Zhang L; Gong J; Fang H; Liu A; Du G; Xu W
J Enzyme Inhib Med Chem; 2011 Aug; 26(4):506-13. PubMed ID: 21143042
[TBL] [Abstract][Full Text] [Related]
15. Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses.
Fu L; Bi Y; Wu Y; Zhang S; Qi J; Li Y; Lu X; Zhang Z; Lv X; Yan J; Gao GF; Li X
J Med Chem; 2016 Jul; 59(13):6303-12. PubMed ID: 27341624
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Ferraris O; Kessler N; Lina B
Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
[TBL] [Abstract][Full Text] [Related]
17. The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.
Mishin VP; Sleeman K; Levine M; Carney PJ; Stevens J; Gubareva LV
Antiviral Res; 2014 Jan; 101():93-6. PubMed ID: 24239666
[TBL] [Abstract][Full Text] [Related]
18. Oseltamivir hydroxamate and acyl sulfonamide derivatives as influenza neuraminidase inhibitors.
Hong BT; Chen CL; Fang JM; Tsai KC; Wang SY; Huang WI; Cheng YE; Wong CH
Bioorg Med Chem; 2014 Dec; 22(23):6647-6654. PubMed ID: 25456388
[TBL] [Abstract][Full Text] [Related]
19. A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.
Tarbet EB; Hamilton S; Vollmer AH; Luttick A; Ng WC; Pryor M; Hurst BL; Crawford S; Smee DF; Tucker SP
J Antimicrob Chemother; 2014 Aug; 69(8):2164-74. PubMed ID: 24777908
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
Zhang H; Wang K; Zhu H; Zhao X; Zhao H; Lei Z; Chen B; Yang F; Liu K; Zhang K; Wang J; Tian Y
Eur J Med Chem; 2020 Aug; 200():112423. PubMed ID: 32512482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
